Jun12682

Jun12682 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PLpro assay. Jun12682 has efficacy in hindering PLpro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PLpro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2[1][2][3].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV; Virus Protease

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/jun12682.html

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=CC=C(C=C1C(N[C@@H](C2=CC(C3=CN(C)N=C3)=CC(C4=NN(CC)C=C4)=C2)C)=O)OCCN(C)C

Molecular Formula

C29H36N6O2

Molecular Weight

500.64

References & Citations

[1]Tan B, et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024 Mar 29;383 (6690) :1434-1440. |[2]Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14 (9) :4189-4192.|[3]Yang M, Kim M, Zhan P. Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice. Acta Pharm Sin B. 2024 Sep;14 (9) :4189-4192.